Fe. Davies et al., The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma, BR J HAEM, 112(3), 2001, pp. 814-819
Initial studies with high-dose therapy (HDT) in myeloma suggest some benefi
cial effects of attaining a complete response (CR); however, the effect on
survival is difficult to assess owing to inconsistencies in the definition
of response between studies. We have analysed 96 newly diagnosed patients a
ged less than 65 years who received HDT and assessed the effect of response
on survival using electrophoresis, immunofixation and fluorescent IgH poly
merase chain reaction (PCR) to define CR. Patients received induction chemo
therapy with C-VAMP (adriamycin, vincristine, methylprednisolone, cyclophos
phamide) followed by melphalan 200 mg/m(2) and reinfusion of peripheral bro
od stem cells. There was a high response to C-VAMP [CR = 24%, partial respo
nse (PR) = 64%], with all but one patient improving the depth of response a
fter HDT (CR = 69%, PR = 31%). The progression-free survival (PFS) and over
all survival (OS) were excellent at a median of 46.4 months and 72+ months,
There was a trend towards an improved PFS in patients with an immunofixati
on-negative CR compared with patients with a PR (49.4 months, 41.14 months:
P = 0.26), This was not evident when electrophoresis was used to define CR
. The method used to define CR did not impact on the overall survival and f
luorescent IgH PCR failed to add any additional prognostic information. Thi
s study supports the widespread use of the European Bone Marrow Transplanta
tion group (EBMT) response criteria and suggests that immunofixation should
be performed on an patients who become electrophoresis negative.